

Andrew Galazka - Biography

(June 6, 2026)



Dr Andrew Galazka is a medically qualified pharmaceutical executive who has worked in senior management (SVP)/ board level roles for a variety of biotech and pharmaceutical companies. Following his medical studies at Cambridge University and postgraduate medical training in the UK, he has worked in the global biopharmaceutical industry for over 35 years (Biogen, GlaxoSmithKline, Serono, Merck Serono). Following his recent retirement from Merck Serono he is now an independent board member, senior advisor to the industry and to investors. He lectures on the development of biopharmaceutical products on the Management of Life Sciences course at the EPFL (the Swiss Federal Institute of Technology) in Lausanne.

He was a board member at Axovan (acquired by Actelion), Addex, a company specialized in allosteric modulation (successfully listed on the Swiss Stock Exchange) and CyteaBio, a start-up specialized in allogeneic effector cells armed with monoclonal antibodies. He was also a board member of Serono Europe, which was responsible for all of Serono's interactions with the EMA for over 20 years. He was scientific advisor to the award winning Neomed IV venture capital fund. He is currently a Board Member at MedXCell, a Swiss biotech venture builder and at Captor Therapeutics SA, a leading company in targeted protein degradation, listed on the Warsaw Stock Exchange.

A seasoned leader, he has a record of leadership in large and small company environments. He has extensive management experience in drug development, especially clinical development, and regulatory strategy. He successfully led drug development programs to regulatory approval and launch in a wide variety of therapeutic areas including autoimmune & inflammatory diseases, oncology, neurology, endocrinology, infectious & tropical diseases, and dermatology. He was responsible for the development of several high-profile products throughout his career, many of which represented significant advances in patient care, and has extensive experience of scientific interactions with key regulatory authorities around the world (principally US, EU, Switzerland, Canada, Australia, Japan). At Merck Serono he and the

team that he led received the Merck 350-Year Anniversary Award from CEO, Dr Belen Garijo, for heading up the global development renaissance of Mavenclad, regarded by many analysts as an impossible prospect, but now transformed into a blockbuster in the treatment of multiple sclerosis. At Serono he received the “Centurion” CEO Award (from Ernesto Bertarelli) for leadership excellence in drug development.

As head of Global Strategic Marketing in New Therapeutic Areas at Serono/ Merck Serono, he was responsible for designing the company’s entry into autoimmunity and oncology.

He made a major contribution to the corporate development of Serono through his senior leadership roles in Development and Strategic Marketing. For a 3-year period at Serono he was also SVP of Investor Relations and Scientific Affairs. Working closely with the CEO and CFO, he spear-headed Serono’s listing on the New York Stock Exchange, thus raising over \$2 billion from institutional investors, resulting in a tripling of the Company’s valuation. Together with his team, he received the Thomson-Extel Award for biotechnology investor relations based on a survey of European buy-side and sell-side analysts.

Education

Dr Galazka earned his medical doctor degree (with distinction) from Cambridge University following a master’s degree in pathology and pharmacology. Following clinical practice, he specialized in pharmaceutical medicine in both the UK (Royal College of Physicians) and Switzerland (FMH). He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK).

Other information

Nationality: British and Swiss

Languages: English, French, Polish